| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Surgery II, Faculty of Medicine, Kyushu University, Fukuoka, Japan
We immunohistochemically examined 131 primary human lung adenocarcinomas for the possible presence of autocrine factors. Transforming growth factor 
(TGF) and epidermal growth factor (EGF) were considered growth factors with epidermal growth factor receptor (EGFR) as the receptor. Of these tumors, 87 (66%) showed a high expression of TGF, 66 (50%) showed a high expression of EGF, and 55 (42%) were positive for EGFR reactivity. In the EGFR-positive cases, the 5-year survival rates of patients with high TGF and low TGF were 36% and 85%, respectively (P < 0.05). The 5-year survival rates of patients with high EGF and low EGF were 25% and 77%, respectively (P < 0.05). In contrast, in the EGFR-negative cases, there was no statistical difference between the 5-year survival rates of patients with either high TGF or EGF and low TGF or EGF. Because autocrine growth mechanisms are present in adenocarcinoma of the human lung, these events may contribute to clarification of tumor development, and perhaps even to a better prognosis.
1 To whom requests for reprints should be addressed at Department of Surgery II, Faculty of Medicine, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812, Japan.
Received 3/ 5/90. Accepted 7/12/90.
This article has been cited by other articles:
|
|
 |
|
  J. V. Abella and M. Park Breakdown of endocytosis in the oncogenic activation of receptor tyrosine kinases Am J Physiol Endocrinol Metab, May 1, 2009; 296(5): E973 - E984. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. E. THEODOROPOULOS, E. KARAFOKA, J. G. PAPAILIOU, P. STAMOPOULOS, C. P. ZAMBIRINIS, K. BRAMIS, S.-G. PANOUSSOPOULOS, E. LEANDROS, and J. BRAMIS p53 and EGFR Expression in Colorectal Cancer: A Reappraisal of 'Old' Tissue Markers in Patients with Long Follow-up Anticancer Res, February 1, 2009; 29(2): 785 - 791. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.D. Hosgood III, I. Menashe, M. Shen, M. Yeager, J. Yuenger, P. Rajaraman, X. He, N. Chatterjee, N. E. Caporaso, Y. Zhu, et al. Pathway-based evaluation of 380 candidate genes and lung cancer susceptibility suggests the importance of the cell cycle pathway Carcinogenesis, October 1, 2008; 29(10): 1938 - 1943. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Witters, P. Scherle, S. Friedman, J. Fridman, E. Caulder, R. Newton, and A. Lipton Synergistic Inhibition with a Dual Epidermal Growth Factor Receptor/HER-2/neu Tyrosine Kinase Inhibitor and a Disintegrin and Metalloprotease Inhibitor Cancer Res., September 1, 2008; 68(17): 7083 - 7089. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Van Dyke, M. L. Cote, G. M. Prysak, G. B. Claeys, A. S. Wenzlaff, V. C. Murphy, F. Lonardo, and A. G. Schwartz COX-2/EGFR expression and survival among women with adenocarcinoma of the lung Carcinogenesis, September 1, 2008; 29(9): 1781 - 1787. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. H. Schiffer, E. C. Reding, S. R. Fuhs, Q. Lu, F. Piu, S. Wong, P.-L. H. Littler, D. M. Weiner, W. Keefe, P. K. Tan, et al. Pharmacology and Signaling Properties of Epidermal Growth Factor Receptor Isoforms Studied by Bioluminescence Resonance Energy Transfer Mol. Pharmacol., February 1, 2007; 71(2): 508 - 518. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Silvestri and M. P. Rivera Targeted Therapy for the Treatment of Advanced Non-small Cell Lung Cancer: A Review of the Epidermal Growth Factor Receptor Antagonists Chest, December 1, 2005; 128(6): 3975 - 3984. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Hurbin, J.-L. Coll, L. Dubrez-Daloz, B. Mari, P. Auberger, C. Brambilla, and M.-C. Favrot Cooperation of Amphiregulin and Insulin-like Growth Factor-1 Inhibits Bax- and Bad-mediated Apoptosis via a Protein Kinase C-dependent Pathway in Non-small Cell Lung Cancer Cells J. Biol. Chem., May 20, 2005; 280(20): 19757 - 19767. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Spano, R. Fagard, J.-C. Soria, O. Rixe, D. Khayat, and G. Milano Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives Ann. Onc., February 1, 2005; 16(2): 189 - 194. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Raben, B. Helfrich, D. C. Chan, F. Ciardiello, L. Zhao, W. Franklin, A. E. Baron, C. Zeng, T. K. Johnson, and P. A. Bunn Jr The Effects of Cetuximab Alone and in Combination With Radiation and/or Chemotherapy in Lung Cancer Clin. Cancer Res., January 15, 2005; 11(2): 795 - 805. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Thompson and C. B. Thompson Putting the Rap on Akt J. Clin. Oncol., October 15, 2004; 22(20): 4217 - 4226. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C-M Huang, C-H Tsai, C-L Chen, C-P Chang, C-C Lai, and F-J Tsai Epidermal growth factor receptor (EGFR) gene Bsr I polymorphism is associated with systemic lupus erythematosus Lupus, October 1, 2004; 13(10): 773 - 776. [Abstract] [PDF]
|
|
|
|
|
|
A. Hurbin, L. Dubrez, J.-L. Coll, and M.-C. Favrot Inhibition of Apoptosis by Amphiregulin via an Insulin-like Growth Factor-1 Receptor-dependent Pathway in Non-small Cell Lung Cancer Cell Lines J. Biol. Chem., December 13, 2002; 277(51): 49127 - 49133. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A-P. Meert, B. Martin, P. Delmotte, T. Berghmans, J-J. Lafitte, C. Mascaux, M. Paesmans, E. Steels, J-M. Verdebout, and J-P. Sculier The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis Eur. Respir. J., October 1, 2002; 20(4): 975 - 981. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Arteaga Epidermal Growth Factor Receptor Dependence in Human Tumors: More Than Just Expression? Oncologist, August 15, 2002; 7(90004): 31 - 39. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. D. Leikauf, M. T. Borchers, D. R. Prows, and L. G. Simpson Mucin Apoprotein Expression in COPD* Chest, May 1, 2002; 121 (2009): 166S - 182S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Arteaga The Epidermal Growth Factor Receptor: From Mutant Oncogene in Nonhuman Cancers to Therapeutic Target in Human Neoplasia J. Clin. Oncol., September 15, 2001; 19(90001): 32s - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Fong, Y. Sekido, and J. D. Minna MOLECULAR PATHOGENESIS OF LUNG CANCER J. Thorac. Cardiovasc. Surg., December 1, 1999; 118(6): 1136 - 1152. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Polosa, G. Prosperini, S.-H. Leir, S. T. Holgate, P. M. Lackie, and D. E. Davies Expression of c-erbB Receptors and Ligands in Human Bronchial Mucosa Am. J. Respir. Cell Mol. Biol., May 1, 1999; 20(5): 914 - 923. [Abstract] [Full Text]
|
|
|
|
 |
|
 F. Bost, R. McKay, M. Bost, O. Potapova, N. M. Dean, and D. Mercola The Jun Kinase 2 Isoform Is Preferentially Required for Epidermal Growth Factor-Induced Transformation of Human A549 Lung Carcinoma Cells Mol. Cell. Biol., March 1, 1999; 19(3): 1938 - 1949. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Bost, R. McKay, N. Dean, and D. Mercola The JUN Kinase/Stress-activated Protein Kinase Pathway Is Required for Epidermal Growth Factor Stimulation of Growth of Human A549 Lung Carcinoma Cells J. Biol. Chem., December 26, 1997; 272(52): 33422 - 33429. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Clarke, R Khakee, and P. McNeil Loss of cytoplasmic basic fibroblast growth factor from physiologically wounded myofibers of normal and dystrophic muscle J. Cell Sci., January 9, 1993; 106(1): 121 - 133. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
